There are several advantages of SLC16A13/MCT13 over MCT1 in terms of a pharmacological target for the treatment of metabolic disease: First, homozygous deletion in mice leads to viable offspring, which is not the case in Slc16a1 knockout mice. The gene discussed is SLC16A1; the disease is metabolic disease.